Pharma R&D company scrutinizes software assets

UK-based FAST Ltd. finds in recent research that 60 percent of companies are under-licensed and 40 percent are over-licensed with their software. It cites Eisai, which manages the functions of marketing and sales, finance, medical information, market research and business operations for the pharmaceutical R&D operations of Eisai Europe and Eisai U.K., as one company that has benefited from implementing a software asset management program. Announcement

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.